ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bennett WM, Schell JO. Why nephrology? podcast. April 13, 2016. Minutes 6:30–7:10. https://www.asn-online.org/media/podcast/ASN/2016_04_13_Why_Nephrology.mp3
-
2.
Lewis EJ, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462. doi: 10.1056/NEJM199311113292004
-
3.
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMoa1504720
-
4.
National Archives. Advancing American Kidney Health. Federal Register, July 10, 2019. Executive Order 13879. https://www.federalregister.gov/documents/2019/07/15/2019-15159/advancing-american-kidney-health
-
5.
Kind R. H.R.5534 – Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020. Congress.gov. 116th Congress (2019–2020). https://www.congress.gov/member/ron-kind/K000188
-
6.
Gill JS, et al. Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act—a chance to celebrate and reflect. J Am Soc Nephrol 2021; 32:774–776. doi: 10.1681/ASN.2020121811
-
7.
Gillibrand KE. S.377 – Living Donor Protection Act of 2021. Congress.gov. 117th Congress (2021–2022). https://www.congress.gov/bill/117th-congress/senate-bill/377?s=1&r=126
-
8.
Porrett PM, Locke JE. A roadmap for human trials of xenotransplantation. J Clin Invest 2022; 132:e164484. doi: 10.1172/JCI164484
-
9.
Carrier AN, et al. Xenotransplantation: A new era. Front Immunol 2022; 13:900594. doi: 10.3389/fimmu.2022.900594
-
10.
Delgado C, et al. A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol 2021; 32:2994–3015. doi: 10.1681/ASN.2021070988
-
11.
US Department of Health and Human Services. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. 2019. https://www.cdc.gov/kidneydisease/pdf/2019_National-Chronic-Kidney-Disease-Fact-Sheet.pdf
-
12.
World Medical Association. Declaration of Geneva 2006. 2006. https://www.wma.net/what-we-do/medical-ethics/declaration-of-geneva/decl-of-geneva-v2006/#:~:text=I%20WILL%20NOT%20PERMIT%20considerations%20of%20age%2C%20disease,for%20human%20life%3B%20WMA%20Declaration%20of%20Geneva%201%2F2
-
13.
National Institutes of Health. Estimates of funding for various research, condition, and disease categories (RCDC). RePORT, Research Portfolio Online Reporting Tools. 2022. https://report.nih.gov/funding/categorical-spending#/
-
14.
Brosius FC, et al. Transforming the care of patients with diabetic kidney disease. Clin J Am Soc Nephrol 2021; 16:1590–1600. doi: 10.2215/CJN.18641120
-
15.
Eggers PW. Medicare's end stage renal disease program. CMS.gov. Centers for Medicare & Medicaid Services, 2000; 22:55–60. https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/HealthCareFinancingReview/List-of-Past-Articles-Items/CMS1191649
-
16.
Scott D. Speak to be heard—becoming my own best advocate. American Association of Kidney Patients. September 21, 2016. https://www.nbcnews.com/id/wbna40842821
-
17.
American Society of Nephrology. Loan Mitigation Pilot Program. 2022. https://www.asn-online.org/education/training/lmp.aspx
ASN President's Update: The Kidney Revolution: Turning a Moment into a Movement
Susan E. Quaggin
Susan E. Quaggin
Susan E. Quaggin, MD, FASN, is with the Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, and is ASN President.
Search for other papers by Susan E. Quaggin in
Current site
Google Scholar
PubMed
Search for other papers by Susan E. Quaggin in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory
Powered by PubFactory